Background Pharmacodynamic (PD) subanalyses of clinical trials in patients with moderate
to severe psoriasis demonstrated the efficacy of apremilast correlated with reductions in …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …

Background Patients with mild-to-moderate psoriasis may have substantial quality-of-life
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …

Apremilast is a small molecule approved for the treatment of plaques psoriasis and adult
psoriatic arthritis. Pivotal studies have demonstrated short and long term efficacy and safety …

We evaluated the pharmacodynamic effects of apremilast in 69 patients who were included
in biomarker subanalyses of a phase 2b study that demonstrated the long‐term safety and …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

OBJECTIVE: To examine real-world use and patient outcomes with apremilast, an oral
PDE4 inhibitor, in the dermatology practice set-ting for treatment of patients with moderate to …

Introduction Patients with mild-to-moderate plaque psoriasis often experience reduced
quality of life and increased disease burden due to itch or involvement of psoriasis in special …